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a  b  s  t  r  a  c  t
Minimal residual disease is the most powerful predictor of outcome in acute leukemia and is
useful in therapeutic stratiﬁcation for acute lymphoblastic leukemia protocols. Nowadays,
the  most reliable methods for studying minimal residual disease in acute lymphoblastic
leukemia are multiparametric ﬂow cytometry and polymerase chain reaction. Both provide
similar results at a minimal residual disease level of 0.01% of normal cells, that is, detec-
tion  of one leukemic cell in up to 10,000 normal nucleated cells. Currently, therapeutic
protocols establish the minimal residual disease threshold value at the most informa-
tive time points according to the appropriate methodology employed. The expertise of the
laboratory in a cancer center or a cooperative group could be the most important factor
in  determining which method should be used. In Brazil, multiparametric ﬂow cytometry
laboratories are available in most leukemia treatment centers, but multiparametric ﬂow
cytometry processes must be standardized for minimal residual disease investigations in
order to offer reliable and reproducible results that ensure quality in the clinical application
of  the method. The Minimal Residual Disease Working Group of the Brazilian Society of BoneMarrow Transplantation (SBTMO) was created with that aim. This paper presents recom-
mendations for the detection of minimal residual disease in acute lymphoblastic leukemia
based  on the literature and expertise of the laboratories who participated in this consensus,
including pre-analytical and analytical methods. This paper also recommends that both
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multiparametric ﬂow cytometry and polymerase chain reaction are complementary meth-
ods,  and so more laboratories with expertise in immunoglobulin/T cell receptor (Ig/TCR) gene
assays are necessary in Brazil.
© 2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by
Elsevier Editora Ltda. All rights reserved.
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inimal residual disease (MRD) is today considered the most
owerful predictor of outcome in acute leukemias, includ-
ng acute lymphoblastic leukemia (ALL). Although classical
actors such as age, cytogenetic and molecular features, and
eukocyte count are taken into account to establish the initial
isk groups for therapeutic purposes, the evaluation of treat-
ent response by MRD  detection allows clinicians to identify
elapse risk categories for ALL and stratify the chemotherapy
ccording to well-established adult or pediatric therapeutic
rotocols.1–7 Results of MRD  studies can also be used to select
reatment intensity and duration, and estimate the optimal
iming for hematopoietic stem cell transplantation (HSCT) in
hildhood ALL.8
Both multiparametric ﬂow cytometry (MFC) and the ampli-
cation of immunoglobulin/T cell receptor (Ig/TCR) genes by
olymerase chain reaction (PCR) have similar results in MRD
etection with a level of 10−4 cells. However the best time
oints for detection are different between the two techniques.
linical  signiﬁcance  of  minimal  residual  disease  levels
he goals of MRD  studies for clinical purposes are to establish:
i) the levels of MRD  that are relevant to the therapeutic deci-
ion; (ii) the most informative time points during treatment;
nd (iii) the clinical relevance of information that each method
rovides at the different time points.
The cut-off value to deﬁne ALL MRD  positivity is 0.01%
r 10−4 cells, because this represents the limit of detection
y immunophenotyping and molecular assays, although it is
ossible to achieve a higher sensitivity (better than 0.01%)
y PCR techniques. Moreover, with the recent improvements
n technology, this threshold can now be achieved by ﬂow
ytometry.8,9 Currently, therapeutic protocols establish a cut-
ff point at the most informative time to predict danger of
elapse according to the appropriate methodology employed
or MRD  detection (Table 1).
The identiﬁcation of the disease relapse risk allows
herapeutic stratiﬁcation and better clinical management,
ncluding recognition of patients who require less intensive
herapy and those eligible for HSCT at ﬁrst remission.5,10
The level of MRD  in pediatric patients prior to condi-
ioning for allogeneic HSCT has a signiﬁcant impact on
ost-transplant outcomes and it is the most important pre-
ictor of relapse after HSCT. Patients with high-level MRD at
he time of transplant (>10−3 or 0.1% malignant cells) have
igniﬁcantly poorer outcomes than those who entered the
ransplantation with negative MRD  (<10−3 cells).11 The AcuteLymphoblastic Leukemia Berlin-Frankfurt-Münster Stem Cell
Transplantation Group (ALL-BFM-SCT) 2003 trial assessed
MRD  in the bone marrow (BM) at Days 30, 60, 90, 180, and
365 after HSCT and each time point with a MRD  ≥10−4
leukemic cells was consistently correlated with shorter event
free survival.12
Two techniques are available for post-transplant mon-
itoring of disease remission: MRD detection and the
characterization of post-transplant chimerism. The MRD
detection techniques search for the malignant clone, while
assessments of chimerism characterize the origin of post-
transplant hematopoiesis.11 The sensitivity of investigations
of chimerism vary greatly depending on the method used.13
Patients with a low MRD level after HSCT (<10−3), can con-
vert mixed chimerism to complete chimerism by pre-emptive
immunotherapy,11,14,15 which demonstrates the importance
of MRD  monitoring after HSCT. Although there is not a well-
established management schedule for these cases, MRD  status
provides a real perspective of rational therapeutic intervention
after HSCT to prevent recurrence of the disease.14
Methods  of  minimal  residual  disease  detection
The most reliable methods of evaluating MRD  are MFC analysis
with the identiﬁcation of leukemia-associated immunophe-
notypes (LAIPs) and amplifying antigen-receptor (Ig/TCR) gene
rearrangements and fusion transcripts by PCR. Both MFC  and
ampliﬁcation of Ig/TCR genes by PCR provide similar results at
a MRD level of 0.01%,5,16 and both MFC and PCR have advan-
tages and disadvantages. MFC  is a rapid method, useful in
>95% of ALL cases and is more  informative than PCR during
the ﬁrst phase of induction therapy, while PCR is preferable for
studies after HSCT or at the end of therapy because of its high
sensitivity in those moments.10,17 During the ﬁrst 2–3 weeks
of remission-induction therapy, BM specimens do not con-
tain lymphoid progenitors, and so the detection of immature
B-cells by MFC can be an indication of residual disease.17
The most important causes of discrepancy between MFC
and PCR assays are: (i) samples containing a limited cell num-
ber for MFC assays; (ii) phenotype variations of regenerating
precursor B-cells (PBC) in BM during therapy and related to
age; (iii) drug induced antigenic modulation; (iv) quality of
PCR clonal markers; (v) ampliﬁcation of nonspeciﬁc DNA from
dead cells; and (vi) oligoclonality and clonal evolution.6,18–20
The main disadvantages of Ig/TCR rearrangement investi-
gations are: (i) they are labor intensive and time consuming; (ii)
require extensive experience and knowledge concerning the
different types of Ig/TCR gene rearrangements; (iii) real-time
PCR technology is demanding because of the design and sen-
sitivity of testing using speciﬁc probe-prime sets for individual
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Table 1 – Clinical signiﬁcance of MRD,  cut-off levels and time points of detection during induction therapy in acute
lymphoblastic leukemia.
Reference Therapeutic
protocol
Cut-off level (%) Method Time point
(induction therapy)
Outcome and
therapy
Cavé H et al. 1998 EORTC >0.1 IgTCR end of
induction
16× higher relapse
rate
Zhou J et al. 2007 Dana-Farber >0.1 IgTCR D30 10,5× higher relapse
rate
Borowitz MJ et al.
2008
COG > 0.01 MFC D29 worst EFS
Flohr T et al. 2008 AEIOP/BFM 2000 ≥  0.01 IgTCR D33 and D78 high relapse rate
Campana D, 2009 St Jude’s ≤ 0.01
>1
≥ 0.01
>1
MFC/PCR D15
D15
D42
D42
low  risk -less
intensive therapy
intensive induction
high-risk
HSCT
Gaipa G et al.
2012
AEIOP/BFM 2000 ≤  0.01 MFC IgTCR D15
D33 and D78
EFS
91,6% (5 years)
Brüggemann M
et al. 2012
GMALL <1,0 × 10−4 MFC/IgTCR D71,w16/w30/
w52
Treatment reduction
high-risk
>1,0 × 10−4
reconversion
<1  year of
treatment
HSCT or
experimental
therapies
MRD, minimal residual disease; MFC, multiparametric ﬂow cytometry; Ig, immunoglobulin; TCR, T-cell receptor; PCR, polymerase chain reaction;
on.EFS, event free survival; HSCT, hematopoietic stem cell transplantati
PCR targets21; and (iv) there are subclones with distinct clonal
Ig/TCR gene rearrangements that are undetected at diagno-
sis and that may become predominant during the course
of the disease (oligoclonality).22 Because of these disadvan-
tages, many  laboratories try to use MFC  for MRD detection,21
although new approaches of sequencing technologies are of
great potential for facilitating molecular MRD  studies in ALL
and may well supplant the current method.23
Immunophenotyping
Detection of MRD  by MFC  consists of searching for LAIPs,
also called aberrant phenotypes, that are absent in nor-
mal, reactive or regenerating BM and peripheral blood cells;
this is useful to discriminate neoplastic cells from nor-
mal  hematopoietic cells. LAIPs include the presence of
cross-lineage antigen expression (e.g. expression of myeloid
antigens in ALL cases), asynchronous patterns of expression of
maturation markers (e.g. surface Ig expression on CD34+ cells)
and abnormal levels of expression of individual markers (e.g.
antigen overexpression or underexpression). LAIPs are identi-
ﬁed in more  than 95% of ALL cases.5,17 Thus, MFC can be used
to monitor 90–95% of MRD  in ALL cases during therapeutic
management. Importantly MRD  can be used with PB samples
in patients with T cell ALL giving similar results to the use of
MRD  testing in BM.  However in patients with B-lineage ALL,
8MRD is usually present at higher levels in BM than in PB; BM
is preferable for MRD  detection in this situation.
The sensitivity of this method varies according to the num-
ber of MFC  colors applied in MRD  assays: 10−3 to 10−4 MRD cellswith 3–4 colors and 10−4 to 10−5 with >6 colors.9 New ways of
sample preparation such as bulk lysis24,25 and improvements
in analysis strategies can also contribute to increase MFC
sensitivity.9 Although these improvements can be achieved in
MRD detection, several studies demonstrated that MRD  mon-
itoring by four-color MFC can still be clinically informative.3,26
The principal advantages of immunophenotyping are: (i)
the possibility of evaluating the sample cellularity and the
degree of hemodilution; (ii) the maturation of normal BM
cells, including lymphoid recovery after immunosuppressive
therapy; (iii) the speed of obtaining results; and (iv) its wide-
ranging applicability.
The limitations of immunophenotyping in MRD studies
are: (i) the low number of cells available; (ii) the similarity of
the immunophenotype between normal precursor cells and
leukemia cells hinders the identiﬁcation of residual blast cells;
(iii) the modulation of antigen expression during treatment18;
(iv) the necessity of high expertise to perform MRD  assays; and
(v) the lack of inter-laboratorial standardization and quality
control.
Immunophenotypic modulation, described in ALL
patients,5,19,27 interferes in the ability to accurately determine
MRD (Table 2). Some modulations of B cell antigen expressions
induced by glucocorticoid therapy19 occur during the ﬁrst
15 days of treatment and persist until Day 33 of induction
therapy. They are characterized by down-modulation of CD10
and CD34 expression and up-modulation of CD19, CD20,
CD45RA and CD11a, while the expression of CD58 is not sig-
niﬁcantly changed compared to levels at diagnosis, either in
BM or in PB samples. At Day 78, after stopping glucocorticoid
rev bras hematol hemoter. 2 0
Table 2 – Common modulation of antigen expression
during acute lymphoblastic leukemia treatment.
B precursor cell ALL T cell ALL
Induction therapy (until Day 33)
Down-modulation of CD10 and
CD34
Up-modulation of CD19, CD20,
CD45RA and CD11a
Induction
therapy
Down-
modulation of
TdT, CD99, CD34
and CD10
At Day 78 of induction
Reversion of CD10 and CD34 to
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protein (PerCP); peridinin-chlorophyll-protein cyanine 5.5initial expression
herapy, there is a reversion of CD10 and CD34 expression
o initial levels and the CD58 expression stablizes.18,19,28
igniﬁcant changes in forward-angle light scatter (FSC) and
ide angle light scatter (SSC) signals associated with blast
ells at diagnosis and at Day 15 are not observed.18
Roshal et al. also described down-modulation of immatu-
ity markers such as TdT, CD99, CD34 and CD10 in T-ALL cells
uring induction therapy. They did not observe intensity vari-
tions in CD2, CD3, CD4, CD5, CD7, and CD8, and CD45 showed
 slight gain in mean ﬂuorescence intensity compared to nor-
al  T cells.27
Furthermore immunophenotypic changes have been
eported in relapsed acute leukemia by clonal selection or lin-
age switch.26 The changes in LAIPs can affect the accuracy
f the ﬂow cytometric detection of MRD  rendering false neg-
tive results. The use of multiple marker combinations can
inimize false negative results suggesting that this should
e a strategy for MRD  detection by immunological methods.
hus, the use of new markers for overexpressed or underex-
ressed PBC ALL compared to normal PBC including CD24,
D44, CD49f, CD69, CD72, CD73, CD79b, CD86, CD97, CD99,
D102, CD123, CD130, CD164, CD200, CD300a, CD304, BCL2,
SPB1, PBX1, CTNNA1, and ITGB7 is promising to improve
ensitivity of immunophenotype MRD  studies.29 In addition,
ome of these markers are associated to genetic abnormali-
ies, and have been proved to be stable after treatment.29
etection  of  minimal  residual  disease  in  acute
ymphoblastic  leukemia  by  multiparametric  ﬂow
ytometry  –  a  proposal  of  standardization
FC  and ampliﬁcation of Ig/TCR genes by PCR have similar
esults at a MRD  level greater than 0.01% cells6,30 but the intro-
uction of MFC  with six or more  colors, the standardization
f instrument settings and immunophenotyping protocols,24
he availability of a robust single multicolor antibody combi-
ation, and novel data analysis strategies,9 may contribute
o improve the potential of MFC  in the diagnosis of MRD.21
he type of laboratory expertise available to a cancer center
r a cooperative group could be the most important factor in
etermining which method should be used.8
In Brazil, as in other countries, there are ﬂow cytometry
aboratories in most leukemia treatment centers, making this
ethod more  readily available.
The MRD  Working Group of the SBTMO was created with
he aim of standardizing MFC  for MRD  investigations and to 1 5;3  7(6):406–413 409
offer reliable and reproducible results that ensure quality in
clinical application and patient care.
Methods
Initially all members of the Working Group reviewed the lit-
erature data; they also evaluated 20 list-mode of normal and
regenerating BM of adult and pediatric samples which were
provided by eight participating centers and available online.
The proposals to standardize MFC presented in this article
are based on reported data and relevant information collected
from the expertise of the participating centers. They include:
(i) protocols for sample preparation and staining, (ii) stan-
dardization of monoclonal antibodies (MoAbs) and respective
ﬂuorochromes, combined in four-color marker panels, (iii)
standardization of MFC acquisition protocols and (iv) quality
control issues.
According to the Brazilian Group of Flow Cytometry
(GBCFLUX) data, most Brazilian MFC laboratories are today
equipped with cytometers with three and four ﬂuorescence
sets. Recently, GBCFLUX published diagnostic panels for acute
leukemia recommended to most Brazilian MFC laboratories.31
The next steps will be to train Working Group members
to support the standardization process and evaluate repro-
ducibility through online interchange of MFC  data ﬁles to
analyze MRD cases as a group. Data analysis is not the goal
of this work and should be addressed in a future paper.
Minimal  residual  disease  working  group  recommendations
General  recommendations
Cell morphology should be assessed visually using conven-
tional optical microscopy. Smears of samples collected in
tubes containing ethylenediaminetetraacetic acid (EDTA) are
also analyzed to estimate the hemodilution parameter. The
smears are internal controls of the laboratory to verify the cel-
lularity of the sample to be processed. Nonetheless, ethically,
all samples must be processed, including hemodiluted sam-
ples. BM (1–2 mL)  or PB samples must be collected in K3 EDTA
(7.5%) for both MFC  and a complete blood count. The storage
of samples should not exceed 24 h after collection (Table 3).
Recommendation  for  sample  preparation
Most laboratories of the MRD Working Group that use
MFC  prepare samples by the conventional stain-and-then-
lyse technique or bulk lysis and stain.25 One laboratory
uses mononuclear cells separated using the Ficoll-Hypaque
method5 according to requirements of the speciﬁc treatment
protocol.
For the conventional technique, fresh BM or PB samples
contain 106 cells, 10–100 L white blood cells must be incu-
bated for 15 min  at room temperature in the dark, with
pre-titrated saturating amounts of four-color combinations
of ﬂuorochrome conjugated MoAb – ﬂuorescein isothio-
cyanate (FITC); phycoerythrin (PE); peridinin-chlorophyll-(PerCPCy5.5); allophycocyanin (APC) (Table 3). As an optional
step, an additional aliquot containing an unstained sam-
ple may be processed in parallel as a negative control.
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Table 3 – Summary of technical proceedings.
General recommendations
Cell morphology of corresponding sample
Evaluation of sample cellularity/hemodilution assessed by
smears from ethylenediaminetetraacetic acid (EDTA) tube
Bone marrow (1–2 mL) or peripheral blood samples must be
collected in K3 EDTA 7.5% for both multiparametric ﬂow
cytometry and complete blood count
The incubation of samples should not exceed 24 h after
collection
Recommendation for sample preparation
Stain-and-then-lyse technique or bulky lysis and stain
Samples incubated for 15 min at room temperature in the dark
with ﬂuorochrome conjugated monoclonal antibodies
Lyse of non-nucleated red cells with lysing solution
Centrifuge and wash twice with PBS or 0.2% PBS–BSA or 0.2%
PBS + BSA plus 0.1% sodium azide
Re-suspend in 300–500 L of PBS for multiparametric ﬂow
cytometry acquisition and analysis
Intracellular staining must be performed after staining for cell
surface membrane markers, utilizing permeabilizing solutions
Standard operational procedures
Daily cleaning and bead calibration procedures
Compensation must be done monthly or when required,
according to the stability of ﬂow cytometer parameters
Routine preventive maintenance must be performed at least
every six months
PBS: phosphate buffer solution; BSA: bovine serum albumin.
Table 4 – Fluorochrome conjugated antibody panels used
for minimal residual disease detection in B precursor
cell-acute lymphoblastic leukemia by multiparametric
ﬂow cytometry.
Mandatory panel
Tube 1 – CD20FITC/CD10PE/CD19PerCP or PEcy5.5/CD34APC
Tube 2 – CD45FITC/CD34PE/CD19PerCP or PEcy5.5/CD38APC
Tube 3 – nTdTFITC/CD10PE/CD19Percp or PEcy5.5/CD34APC
Recommended tubesa
Tube 4 – CD81FITC/CD66cPE/CD19PerCP or PEcy5.5/CD34 APC
Tube 5 – CD45FITC/CD123PE/CD19PerCP or PEcy5.5/CD34APC
Tube 6 – CD15FITC and CD65FITC/NG2PE/CD45PerCP/CD19APC
Optional markersa
CD13 and/or CD33 PE, CD58FITC, CD9FITC/CD25PE, CD22PE
n: nuclear staining.Non-nucleated red cells can be lysed using FACS Lysing solu-
tion (Becton-Dickinson Biosciences -BDBTM, San Jose, CA, USA)
or Excellyse Easy (ExbioTM, Vestec, Czech Republic), accord-
ing to the manufacturer’s instructions. The remaining cells
are sequentially centrifuged (500 g) for 5 min, washed twice
in phosphate buffered saline (PBS: pH 7.4) or PBS plus 0.2%
bovine serum albumin (BSA: pH 7.4) or PBS plus 0.2% BSA plus
0.1% sodium azide: pH 7.4) and re-suspended in 300–500 L
in PBS for MFC  acquisition and analysis. Intracellular staining
for CD3 and TdT is performed after staining for cell surface
membrane markers using Fix&Perm solution (InvitrogenTM,
Camarillo, CA, USA or An Der GrubTM, Vienna, Austria) or
the Intra Stain kit (DakoTM, Carpinteria, CA, USA) as per the
instructions of the manufacturer. The recommended solu-
tions have been tested, applied and selected for use in most
of the laboratories of the Working Group.
Standard  operational  procedures
Daily cleaning and calibration of bead procedures are rec-
ommended and compensation should be done every month
or when required according to stability of ﬂow cytometer
parameters. Flow cytometer performance must be checked
every day or according to the manufacturer’s recommenda-
tions to ensure that the evaluation of samples always uses
the same parameters and enable an accurate analysis of
the underexpression and overexpression of markers which is
very important for MRD  detection. Routine preventive main-
tenance must be performed periodically, that is, at least every
six months (Table 3).a According to antigen expression at diagnosis.
Fluorochrome  selection  for  four-color  panels
The selection of the most appropriate combination of ﬂuo-
rochromes for four-color panels should allow simultaneous
usage of backbone markers aimed at the identiﬁcation of the
cell populations of interest and additional antibody markers
devoted to a more  detailed characterization of the leukemic
cell populations such as maturation markers, cross-lineage
markers, and markers associated with molecular lesions. A
combination of FITC, PE, PerCP or PECy5.5 and APC were
selected based on the literature and the expertise of the Work-
ing Group.
Immunophenotypic abnormalities of leukemic B cell popu-
lations are identiﬁed by the deviation from normal patterns
of B-lymphoid development9. PBC or hematogones have mor-
phologic and immunophenotypic similarities to neoplastic
lymphoblasts. PBC may be present in large numbers in many
situations as early as infancy, or in a variety of diseases
both in childhood and in adult life, as in some autoim-
mune and congenital cytopenias, neoplasms and acquired
immunodeﬁciency syndrome (AIDS).32 Hematogones also
may be particularly prominent in regenerating BM following
chemotherapy or HSCT (Figure 1).32–35 Particularly follow-
ing ALL treatment, hematogones are often expanded in BM
and can potentially be mistaken for residual disease. Some
studies showed that the PBC population always expresses a
continuous and complete maturation spectrum by four-color
ﬂow cytometry.36 In contrast, cases of PBC ALL frequently
show a different spectrum to normal B-lineage maturation.
These differences include: maturation arrest; overexpression,
underexpression, and asynchronous expression of antigens
observed in PBC and often the expression of myeloid-
associated antigens.33,37
According to this MRD Working Group consensus, residual
B-cell ALL must be investigated in BM and identiﬁed by two
backbone markers in a four-color MoAb panel, such as CD19
and CD34.
The mandatory panel for B-cell ALL MRD detection
(Table 4) is addressed to identify deviations in the maturation
pathway of B-cells and verify alterations in the antigen
expression patterns: Tube 1: CD20FITC/CD10PE/CD19PerCP or
PEcy5.5/CD34APC (Figure 1), Tube 2: CD45FITC/CD34PE/
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Figure 1 – Minimal residual disease in precursor B-cell acute lymphoblastic leukemia using maturation tube:
CD20FITC/CD10PE/CD19PerCP/CD34APC. (A) At diagnosis (77.6% of blast cells) and (B) the same patient on Day 15 of
induction therapy with positive minimal residual disease (0.03%). (C) MLLAF4 precursor B-cell acute lymphoblastic leukemia
with positive minimal residual disease (0.28%) on Day 40 after hematopoietic stem cell transplantation. (D and E) BCR-ABL
positive precursor B-cell acute lymphoblastic leukemia with positive minimal residual disease (0.32%) before conditioning
treatment for hematopoietic stem cell transplantation. Gate in CD 19+ cells. In green: mature B-cells (A–C), normal precursor
and mature B-cells (D and E). In red: blast cells. In blue: normal CD 34+ precursor B-cells. Acquisition: 1,000,000 of total
e
C
F
t
t
s
c
p
l
1
t
B
c
p
c
l
a
m
s
e
o
t
Table 5 – Fluorochrome conjugated antibody panels used
for minimal residual disease detection in T cell-acute
lymphoblastic leukemia by multiparametric ﬂow
cytometry.
Mandatory panel
Tube 1 – cyCD3FITC/mCD3PE/CD45PerCP/CD7APC
Tube 2 – nTdTFITC/CD2PE/CD5PerCP/CD7APC
Recommended tube
Tube 3 – CD1aFITC/CD99PE/mCD3PerCP/CD7APC
Optional markersa
CD10PE, CD13PE, CD33PE, CD 34 PE, CD44PE, CD117PE
cy: cytoplasmic staining; n: nuclear staining; m: membrane
F
i
cvents. Method: bulk lysis.
D19PerCP or PEcy5.5/CD38APC and Tube 3: nTdT-
ITC/CD10PE/CD19PerCP or PEcy5.5/CD34APC.
Recommended tubes are intended to recognize: (i) markers
hat are frequently underexpressed in B cell ALL compared
o normal B-cells such as CD81; (ii) cross-lineage markers
uch as CD15, CD65, CD66c, CD123; and (iii) markers asso-
iated with molecular lesions such as CD66c [in some cases
resenting the breakpoint cluster region-Abelson murine
eukemia (BCR-ABL) fusion protein] and NG2 (associated with
1q23 alterations); this latter one is often expressed concomi-
antly to CD15 and/or CD65 (Figure 1).
Optional markers are: CD9 and CD22 that are expressed in
 normal cells and often underexpressed in their leukemic
ounterparts; CD58 that has been shown to be overex-
ressed in leukemic blasts when compared to their normal
ounterparts,28 CD13 and CD33 (myeloid markers) as cross-
ineage markers and CD25 (interleukin 2 receptor) can also be
ssociated with the presence of BCR-ABL positive PBC ALL. It
ust be emphasized that recommended and optional markers
hould be chosen according to their expression at diagnosis.
MRD  detection of T-ALL in the PB or BM is theoretically
asier as most stages of normal T lymphocyte maturation
ccur in the thymus. Therefore the presence of an imma-
ure T cell subset in the PB or BM should be considered
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aberrant. For the investigation of MRD in T-cell ALL, CD3
and CD7 are recommended as backbone markers (Table 5).
Mandatory and recommended tubes are addressed to iden-
tify maturation stage of blast cells and include immaturity
markers such as TdT, CD34, CD1a, and CD99 (Figure 2). Dif-
ﬁculties in MRD detection in T-ALL largely stem from the loss
of immaturity markers on the abnormal blast population fol-
lowing induction chemotherapy. Optional markers for T-ALL
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MRD  aim to recognize cross-lineage markers such as CD13 and
CD33; a marker that is underexpressed or overexpressed in
81% of T-ALL cases such as CD44,29 and CD117, expressed in
early T-ALL. These markers may be useful for MRD detection
when they are expressed at diagnosis.
Data  acquisition
Data acquisition must be performed in sequence immedi-
ately after sample preparation is completed. For each sample
aliquot, a minimum of 500,000 and maximum of 1,000,000
events must be acquired. Optionally, laboratories that perform
bulk lysis are able to acquire 5,000,000 events. A criterion for
quantiﬁable MRD  positivity was established using a detection
limit of absolute MRD  cell counts of 10 cells or more  in each
tube.38
Conclusion
MFC  is a powerful method for MRD  investigations of
hematology malignancies, but it is fundamental to have
good standardization of the pre-analytical, analytical and
post-analytical processes. The MRD  Working Group recom-
mendations meet this requirement with the main goal being
the patients’ safety and care. For this purpose, it also should be
stressed that the MFC  and PCR techniques are complementary,
and so it is necessary that more  molecular biology laboratories
with expertise in Ig/TCR assays are available in Brazil.
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